Approved by the FDA, EMA and other global regulatory authorities, Buprenorphine is indicated in the treatment of opioid use disorder and pain. Existing medications encompass both monotherapy and combination therapy dose forms.
We are a producer of Naloxone for reversing opioid overdose and in combination therapy for opioid use disorder. We also produce Naltrexone for treating alcohol and opioid use disorders. Current research is investigating how our platform can be harnessed to manufacture other ‘Nal Group’ compounds.
Our Hybrid Platform is Solving Industry Challenges
Traditional methods of producing alkaloid APIs are complex, environmentally challenging and expensive. River Stone Biotech’s manufacturing and process development capabilities couple fermentation with improved chemistry methodology. This combination approach enables flexible intermediates to be taken into more streamlined chemistry conversion processes, driving efficiencies across many criteria. The result is a first-in-kind platform that solves key industry challenges – reducing complexity, waste and cost.Our Focus
Our priority focus is on the very expensive APIs buprenorphine, naloxone and naltrexone – used in treatments for opioid use disorder, alcohol use disorder, opioid overdose and pain. In line with high prevalence of these indications, we expect an increasing need for production of these life-changing APIs.Our Focus
View our select investor presentations and scientific publications for the latest information and updates.View Now
Working together we can create successful partnerships to
enable and expand our API offering.